CN101410714A - 在克罗恩病患者的外周血白细胞中T细胞受体介导的肿瘤坏死因子超家族与趋化因子mRNA增强的表达 - Google Patents

在克罗恩病患者的外周血白细胞中T细胞受体介导的肿瘤坏死因子超家族与趋化因子mRNA增强的表达 Download PDF

Info

Publication number
CN101410714A
CN101410714A CNA2007800115431A CN200780011543A CN101410714A CN 101410714 A CN101410714 A CN 101410714A CN A2007800115431 A CNA2007800115431 A CN A2007800115431A CN 200780011543 A CN200780011543 A CN 200780011543A CN 101410714 A CN101410714 A CN 101410714A
Authority
CN
China
Prior art keywords
sample
ratio
leucocyte
mrna
tnfsf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800115431A
Other languages
English (en)
Chinese (zh)
Inventor
三桥将人
斯蒂芬·R·塔尔甘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resonac Corp
Cedars Sinai Medical Center
Resonac America Inc
Original Assignee
Hitachi Chemical Co Ltd
Cedars Sinai Medical Center
Hitachi Chemical Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hitachi Chemical Co Ltd, Cedars Sinai Medical Center, Hitachi Chemical Research Center Inc filed Critical Hitachi Chemical Co Ltd
Publication of CN101410714A publication Critical patent/CN101410714A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA2007800115431A 2006-04-07 2007-04-05 在克罗恩病患者的外周血白细胞中T细胞受体介导的肿瘤坏死因子超家族与趋化因子mRNA增强的表达 Pending CN101410714A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79035406P 2006-04-07 2006-04-07
US60/790,354 2006-04-07

Publications (1)

Publication Number Publication Date
CN101410714A true CN101410714A (zh) 2009-04-15

Family

ID=38581650

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800115431A Pending CN101410714A (zh) 2006-04-07 2007-04-05 在克罗恩病患者的外周血白细胞中T细胞受体介导的肿瘤坏死因子超家族与趋化因子mRNA增强的表达

Country Status (6)

Country Link
US (1) US7838239B2 (enExample)
EP (1) EP2005175B1 (enExample)
JP (1) JP5027209B2 (enExample)
CN (1) CN101410714A (enExample)
AT (1) ATE518011T1 (enExample)
WO (1) WO2007117611A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776471B9 (en) * 2004-05-25 2013-12-18 Hitachi Chemical Company, Ltd. Method of measuring cancer susceptibility
JP4772055B2 (ja) * 2004-10-20 2011-09-14 日立化成工業株式会社 ｍＲＮＡの定量により薬剤の投与を選定する方法
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
JP4945554B2 (ja) * 2005-04-28 2012-06-06 ヒタチ ケミカル リサーチ センター インコーポレイテッド 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現
WO2009070442A2 (en) 2007-11-14 2009-06-04 Hitachi Chemical Co. Ltd. Fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes
DE102006051628A1 (de) 2006-11-02 2008-05-08 Daimler Ag Abgasturbolader für eine Brennkraftmaschine
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
EP2056110A1 (en) 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
US20110229471A1 (en) * 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
EP2992792B1 (en) * 2010-11-11 2017-03-15 Nestec S.A. Beverage production machine and rinsing and/or descaling insert
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
EP2734233B1 (en) * 2011-07-18 2017-11-01 Hitachi Chemical Co., Ltd. Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CN103865998B (zh) * 2013-12-16 2016-04-20 周菊华 一种肿瘤免疫治疗效果的基因检测方法
US20150257586A1 (en) * 2014-03-11 2015-09-17 Starbucks Corporation Dba Starbucks Coffee Company Single-serve beverage production machine
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925572A (en) 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4880548A (en) 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
PT938320E (pt) 1996-03-26 2010-09-22 Michael S Kopreski Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro
US5683698A (en) 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US6183951B1 (en) * 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
US20020006613A1 (en) 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies
WO2000076492A1 (en) 1999-06-15 2000-12-21 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US20020048566A1 (en) 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
US7374881B2 (en) * 2000-10-31 2008-05-20 Hitachi Chemical Research Center, Inc. Method for collecting and using nuclear mRNA
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
JP5236856B2 (ja) * 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
CA2467629A1 (en) 2001-11-20 2003-05-30 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6878518B2 (en) 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
US7745180B2 (en) 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
EP1507548B1 (en) 2002-05-27 2014-10-01 CanImGuide Therapeutics AB Method for determining immune system affecting compounds
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
EP1776471B9 (en) 2004-05-25 2013-12-18 Hitachi Chemical Company, Ltd. Method of measuring cancer susceptibility
US8110347B2 (en) 2005-04-15 2012-02-07 Canimguide Therapeutics Ab Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6
JP4945554B2 (ja) 2005-04-28 2012-06-06 ヒタチ ケミカル リサーチ センター インコーポレイテッド 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現
US7935482B2 (en) 2005-09-27 2011-05-03 Source Precision Medicine, Inc. Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease

Also Published As

Publication number Publication date
JP5027209B2 (ja) 2012-09-19
EP2005175A2 (en) 2008-12-24
WO2007117611A3 (en) 2008-08-07
EP2005175A4 (en) 2009-06-03
US7838239B2 (en) 2010-11-23
US20090253133A1 (en) 2009-10-08
ATE518011T1 (de) 2011-08-15
EP2005175B1 (en) 2011-07-27
JP2009535016A (ja) 2009-10-01
WO2007117611A2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
CN101410714A (zh) 在克罗恩病患者的外周血白细胞中T细胞受体介导的肿瘤坏死因子超家族与趋化因子mRNA增强的表达
JP5727484B2 (ja) Ｉ型インターフェロン診断法
Sonkoly et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation
US8268566B2 (en) Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis
CN101194027B (zh) 用于基于瘤细胞及受刺激的白细胞内mRNA表达谱而预测对肿瘤疾病的免疫应答的方法
Al-Alami et al. Familial Mediterranean fever mutation frequencies and carrier rates among a mixed Arabic population
NZ573052A (en) Hepatitis c virus infection biomarkers
Zhao et al. The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept
US20120258076A1 (en) Method for characterizing host immune funtion by ex vivo induction of offensive and defensive immune markers
JP2013526845A (ja) サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ
Yadav et al. Evidence for persistent monocyte and immune dysregulation after prolonged viral suppression despite normalization of monocyte subsets, sCD14 and sCD163 in HIV-infected individuals
JP5837691B2 (ja) 白血球機能関連ｍＲＮＡの生体外での誘導によって癌免疫療法に対するホストの応答性を予測する方法
US20090311684A1 (en) Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis
Torres-Vázquez et al. Relationship of IP-10 gene expression to systemic lupus erythematosus activity
JP6347477B2 (ja) 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法
US9150920B2 (en) Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers
US20170003277A1 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
AU2011268223B2 (en) Method for predicting a therapy response in subjects with multiple sclerosis
Hamed et al. Association of interleukin-6 and its-174G/C promoter polymorphism with clinical and laboratory characteristics of non hepatitis C virus rheumatoid arthritis patients
Kolić et al. Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis
Mariani Can (immune and other) gene expression help us to treat depression?
Mitsuhashi Ex vivo simulation of leukocyte function: stimulation of specific subset of leukocytes in whole blood followed by the measurement of function-associated mRNAs
US20160265058A1 (en) Diagnostic methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
Aldaoseri et al. Determining what happens to the genes FOXP3, RORγt, SOCS1, STAT3, STAT5, and SMAD3 in patients with ankylosing spondylitis who received anti-TNF therapy
Fang et al. Identification of Key Immune-Related Genes, Molecular Pathways and Immune Infiltration as Diagnostic and Therapeutic Candidate Targets for RA: an integrated bioinformatics-based analysis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090415